Check out our new Timeline feature to give you the latest updates on all the stocks you follow. Clickhere to set up your Timeline.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here
SEEEN plc CEO, Adrian Hargrave, discusses operational & trading highlights & outlook for 2025
SEEEN plc CEO, Adrian Hargrave, discusses operational & trading highlights & outlook for 2025View Video
Majestic Corporation: An Introduction to Urban Mining and Critical Mineral Recycling
Majestic Corporation: An Introduction to Urban Mining and Critical Mineral RecyclingView Video

Latest Share Chat

MaxCyte appoints new chief commercial officer

Thu, 10th Oct 2024 13:23

(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Ali Soleymannezhad as its new chief commercial officer on Thursday, effective from 11 September.

The AIM-traded firm said in the role, Soleymannezhad would oversee its commercial operations, aiming to drive greater adoption of the 'ExPERT' platform, provide top-tier scientific, technical, and regulatory support to customers, and expand its market influence in the cell and gene therapy sectors.

Soleymannezhad would bring 20 years of experience in technical sales, marketing, and product development to his new position.

Before becoming executive vice-president of bioprocessing at MaxCyte, he held the role of executive vice-president for the separations and purification business at Tosoh Bioscience, managing a team of 140 employees across four global manufacturing, development, and commercial sites.

He also served as vice-president of global marketing and business development, director of sales and marketing for the Americas at Tosoh, and was a board member of Semba Biosciences.

"I am delighted to promote Ali to the role of chief commercial officer," said president and chief executive officer Maher Masoud.

"His diverse experience, skills, and leadership at MaxCyte as executive vice-president of bioprocessing have strengthened our organisation's product development and commercial strategies.

"We look forward to working alongside Ali as he leads our commercial efforts to drive future growth at MaxCyte."

At 1115 BST, shares in MaxCyte were up 0.71% at 285p.

Reporting by Josh White for Sharecast.com.

Related Shares

More News
12 Feb 2025 10:21

MaxCyte signs SPL deal with TG Therapeutics

(Sharecast News) - MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the biopharmace...

12 Feb 2025 09:30

MaxCyte partners with TG Therapeutics on autoimmune cell therapy

(Alliance News) - MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell the...

30 Jan 2025 16:43

MaxCyte announces acquisition of SeQure Dx

(Sharecast News) - MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services ...

30 Jan 2025 13:55

MaxCyte buys gene therapy analytics firm SeQure Dx

(Alliance News) - MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process.

13 Jan 2025 14:34

MaxCyte flags full-year revenue at top end of expectations

(Sharecast News) - Cell-engineering platform technology company MaxCyte said in an update on Friday that it expected core revenue for the fourth quart...

Track Your Investments

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.